A Randomised, Double-blind, Placebo-controlled (Within Dose Groups) Study to Assess Safety, Tolerability and Pharmacokinetics of Single Rising Inhaled Doses (2.5 μg, 5 μg, 10 μg, 20 μg and 40 μg) of BI 1744 CL (Administered With the Respimat®) in Free Dose Combination With Tiotropium Bromide 5 μg ( for Doses up to and Including 20 μg BI 1744 CL), 10 μg (for Doses of 20 μg and 40 μg BI 1744 CL) (Administered With the Respimat®) in Healthy Male Volunteers
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 48
- 主要终点
- Number of participants with abnormal findings in physical examination
研究概览
简要总结
Study to investigate safety and tolerability of single, inhaled doses (2.5 μg, 5 μg, 10 μg, 20 μg and 40 μg) of BI 1744 CL in free dose combination with tiotropium bromide 5 μg (for doses up to and including 20 μg BI 1744 CL) and 10 μg (for doses of 20 μg and 40 μg BI 1744 CL), both administered by Respimat® in healthy male volunteers. Also, to investigate the pharmacokinetics of BI 1744 BS and tiotropium bromide in such combinations, to explore their dose proportionality, and to explore the pharmacodynamic effects of the treatments on selected metabolic and respiratory parameters
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 21 Years 至 50 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Healthy male based upon a complete medical history, including the physical examination, regarding vital signs (Blood Pressure (BP), Pulse Rate (PR)), 12-lead ECG measurement, and clinical laboratory tests. Absence of any clinically relevant abnormality. Absence of any clinically relevant concomitant disease
- •Age ≥21 and ≤50 years
- •BMI ≥18.5 and <30 kg/m2 (Body Mass Index)
- •Signed and dated written informed consent prior to admission to the study in accordance with Good Clinical Practice (GCP) and the local legislation
排除标准
- •Any finding of the medical examination (including BP, PR, and ECG measurements) deviating from normal and of clinical relevance
- •Evidence of a clinically relevant concomitant disease
- •Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
- •Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
- •History of relevant orthostatic hypotension, fainting spells or blackouts
- •Chronic or relevant acute infections
- •History of relevant allergy/hypersensitivity (including allergy to the drug or its excipients) as judged clinically relevant by the investigator
- •Intake of drugs with a long half-life (>24 hours) within at least 1 month or less than 10 half-lives of the respective drug prior to randomization
- •Use of drugs which might reasonably influence the results of the trial based on the knowledge at the time of protocol preparation within 10 days prior to enrolment in the study or during the study
- •Participation in another trial with an investigational drug within 2 months prior to randomization
- •Smoker (>10 cigarettes or >3 cigars or >3 pipes/day)
- •Inability to refrain from smoking on trial days as judged by the investigator
- •Alcohol abuse (regularly more than 40 g alcohol per day for men)
- •Blood donation (more than 100 mL blood within 4 weeks prior to randomisation or during the trial)
- •Excessive physical activities within 1 week prior to randomization or during the trial
- •Any laboratory value outside the reference range that is of clinical relevance
- •Inability to comply with dietary regimen of the study centre
- •Additionally, following exclusion criteria that are of particular relevance with regard to the known properties of BI 1744 CL as a ß-adrenoceptor agonist must be adhered to:
- •Asthma or history of pulmonary hyperreactivity
- •Hyperthyrosis
- •Allergic rhinitis in need of treatment
- •Clinically relevant cardiac arrhythmia
- •Paroxysmal tachycardia
- •Furthermore, the following exclusion criteria that are of particular relevance with regard to the known properties of tiotropium as an antimuscarinic anticholinergic agent must be adhered to:
- •Hypersensitivity to tiotropium and/or related drugs of these classes
- •History of narrow-angle glaucoma
- •History of prostatic hyperplasia
- •History of bladder-neck obstruction
研究组 & 干预措施
BI 1744 CL - single rising dose + Tiotropium
Single rising dose of BI 1744 CL (conjointly with Tiotropium bromide)
干预措施: BI 1744 CL (Drug)
BI 1744 CL - single rising dose + Tiotropium
Single rising dose of BI 1744 CL (conjointly with Tiotropium bromide)
干预措施: Tiotropium bromide (Drug)
Placebo
干预措施: Placebo (Drug)
结局指标
主要结局
Number of participants with abnormal findings in physical examination
时间窗: up to 12 days after drug administration
Number of participants with adverse events
时间窗: up to 12 days after drug administration
Number of abnormal findings on oropharyngeal inspection
时间窗: up to 24 hours after drug administration
Number of abnormal findings on pulmonary auscultation
时间窗: up to 24 hours after drug administration
Change in Cyclic aminomonophosphate (cAMP)
时间窗: up to 6 hours after drug administration
Number of participants with abnormal changes in laboratory parameters
时间窗: up to 12 days after drug administration
Number of participants with clinically significant changes in vital signs
时间窗: up to 12 days after drug administration
blood pressure (BP), pulse rate (PR), respiratory rate (RR)
Number of participants with clinically significant changes in 12-lead ECG
时间窗: up to 12 days after drug administration
cardiac axis, heart rate, PQ interval, QRS interval, uncorrected QT interval, HR-corrected QT-interval according to Bazett and Fridericia
Assessment of tolerability by investigator on a 4-point scale
时间窗: 12 days after drug administration
Change in Airway resistance (Raw)
时间窗: up to 24 hours after drug administration
measured by whole-body plethysmography
Change in specific conductance (sGaw)
时间窗: up to 24 hours after drug administration
measured by whole-body plethysmography
Change in potassium
时间窗: up to 6 hours after drug administration
次要结局
- tmax (time from dosing to maximum measured concentration)(up to 96 hours after drug administration)
- AUC0-∞ (area under the concentration-time curve of BI 1744 BS and tiotropium in plasma over the time interval from 0 extrapolated to infinity)(up to 96 hours after drug administration)
- Cmax (maximum measured concentration of BI 1744 BS and tiotropium in plasma)(up to 96 hours after drug administration)
- AUC0-tz (area under the concentration-time curve of the analyte salmeterol in plasma over the time interval from 0 to the time of the last quantifiable data point)(up to 96 hours after drug administration)
- %AUCtz-∞ (percentage of the extrapolated part of the total AUC0-∞)(up to 96 hours after drug administration)
- Aet1-t2 (amount of BI 1744 BS and tiotropium eliminated in urine from the time point t1 to time point t2)(up to 96 hours after drug administration)
- t1/2 (terminal half-life of BI 1744 BS and tiotropium in plasma)(up to 96 hours after drug administration)
- MRTih (mean residence time of BI 1744 BS and tiotropium in the body after inhalation)(up to 96 hours after drug administration)
- λz (terminal rate constant in plasma)(up to 96 hours after drug administration)
- CL/F (apparent clearance of BI 1744 BS and tiotropium in plasma after extravascular administration)(up to 96 hours after drug administration)
- Vz/F (apparent volume of distribution during the terminal phase λz following an extravascular dose)(up to 96 hours after drug administration)
- fet1-t2 (fraction of BI 1744 BS and tiotropium eliminated in urine from time point t1 to time point t2)(up to 96 hours after drug administration)
- CLR,t1-t2 (renal clearance of BI 1744 BS and tiotropium from the time point t1 until the time point t2)(up to 96 hours after drug administration)